Peptides: Part 1 of 2 parts -The Master Molecules of Human Health — What They Are, What They Do, and Why They Matter Part 1 of 2

Introduction: The Molecules Running the Show

If proteins are the workhorses of the human body, peptides are the foremen — the precise, targeted signaling molecules that tell every system in your body what to do, when to do it, and how much. They regulate hormones, modulate immunity, repair tissue, govern inflammation, direct cellular communication, and even influence gene expression. Yet most people have never heard of them.

Peptides are not a fringe concept. They are the subject of thousands of peer-reviewed studies, Nobel Prize-winning research, and an exploding field of pharmaceutical and nutraceutical development. Understanding peptides is, in many ways, understanding the operating system of human biology.

This is Part 1 of a two-part series. Here we cover the fundamentals: what peptides are, how many exist, what they do, what happens when they decline, and what the emerging science says about their role in immune disease and cancer. Part 2 covers testing, natural optimization strategies, and the critical question of self-treatment versus working with a qualified practitioner.

What Are Peptides?

A peptide is a short chain of amino acids — the same building blocks that make up proteins. The distinction is size: peptides are generally defined as chains of 2 to 50 amino acids, while proteins are longer chains (typically 50+ amino acids). This size difference is not merely semantic — it has profound implications for how these molecules behave in the body.

Because of their smaller size, peptides are highly bioactive, able to cross cell membranes, penetrate the blood-brain barrier, and interact with specific receptors with extraordinary precision. They act as biological keys, fitting into receptor locks throughout the body to trigger cascades of physiological responses — from releasing growth hormone to modulating immune function to accelerating wound healing.

Peptides are synthesized in the body from dietary amino acids through a process called ribosomal synthesis, though many are also produced through enzymatic cleavage of larger proteins. They are found in every tissue and organ system, and their activity is tightly regulated by the body's internal feedback mechanisms.

As Dr. Andrew Huberman, neuroscientist at Stanford University, has noted: "Peptides are among the most powerful signaling molecules in biology. They are not exotic — they are fundamental to how the body regulates itself at every level."^[1]

How Many Peptides Exist?

The number of peptides in the human body is staggering. Current estimates suggest there are over 7,000 naturally occurring bioactive peptides identified in the human body and food sources combined, with new ones being discovered regularly as proteomics research advances.^[2]

The human genome encodes approximately 20,000–25,000 proteins, and each of these proteins can be cleaved into multiple peptide fragments — many of which are themselves biologically active. When you factor in post-translational modifications (chemical changes that occur after a peptide is synthesized), the functional peptidome — the complete set of peptides active in the body at any given time — is virtually limitless in its complexity.

Key categories of endogenous (body-produced) peptides include:

• Neuropeptides — signaling molecules in the nervous system (e.g., endorphins, substance P, neuropeptide Y)
• Hormonal peptides — including insulin, glucagon, oxytocin, vasopressin, and growth hormone-releasing hormone (GHRH)
• Antimicrobial peptides (AMPs) — the body's innate immune defense molecules (e.g., defensins, cathelicidins)
• Cytokine peptides — immune modulators including interleukins and interferons
• Structural peptides — collagen-derived peptides that support connective tissue integrity
• Regulatory peptides — including thymosin alpha-1, BPC-157, and epithalon, which regulate organ function and cellular repair
• Food-derived bioactive peptides — released during digestion from dietary proteins (casein, whey, soy, egg, fish)

In the pharmaceutical world, over 80 peptide-based drugs are currently FDA-approved, with hundreds more in clinical trials. The global peptide therapeutics market is projected to exceed $50 billion by 2030 — a testament to how seriously the medical establishment takes these molecules when it suits commercial interests.^[3]

What Do Peptides Do? The Major Biological Roles

Peptides are involved in virtually every physiological process in the human body. Below are the major functional categories:

1. Hormonal Regulation

Many of the body's most critical hormones are peptides. Insulin — the master metabolic hormone — is a 51-amino-acid peptide. Glucagon, its counterpart, is a 29-amino-acid peptide. Growth hormone-releasing hormone (GHRH) stimulates the pituitary to release growth hormone. Oxytocin, the "bonding hormone," is a 9-amino-acid peptide. These molecules govern metabolism, growth, reproduction, stress response, and social behavior.

2. Immune Modulation

The immune system is profoundly peptide-dependent. Antimicrobial peptides (AMPs) are the body's first line of innate immune defense — they disrupt bacterial membranes, neutralize viruses, and modulate inflammatory responses. Thymosin alpha-1, a peptide produced by the thymus gland, is one of the most studied immune-regulatory peptides, with documented effects on T-cell maturation, NK cell activity, and cytokine balance.^[4]

Dr. Allan Goldstein, the biochemist who first isolated thymosin alpha-1 at George Washington University, described it as "the master regulator of immune function — a molecule capable of restoring immune competence in states of profound immunodeficiency."^[5]

3. Tissue Repair and Regeneration

BPC-157 (Body Protection Compound 157), a 15-amino-acid peptide derived from a protein found in gastric juice, has been extensively studied for its regenerative properties. Research published in peer-reviewed journals has demonstrated its ability to accelerate healing of tendons, ligaments, muscles, and gut tissue, as well as its neuroprotective and cardioprotective effects.^[6] While most research has been conducted in animal models, the mechanistic data is compelling and has driven significant interest in the functional medicine community.

4. Neurological Function

Neuropeptides are the chemical language of the nervous system. Endorphins (endogenous opioid peptides) modulate pain and reward. Neuropeptide Y regulates appetite, stress response, and circadian rhythm. Substance P is involved in pain transmission and neuroinflammation. BDNF (brain-derived neurotrophic factor), while technically a protein, is regulated by peptide signaling cascades and is critical for neuroplasticity and cognitive function.

5. Cardiovascular Function

Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are cardiac peptides that regulate blood pressure, fluid balance, and cardiac remodeling. BNP is now a standard clinical biomarker for heart failure. Angiotensin II, a vasoconstrictor peptide, is central to blood pressure regulation and is the target of ACE inhibitor medications.

6. Gut Health and Digestion

The gastrointestinal tract is one of the richest sources of peptide signaling in the body. GLP-1 (glucagon-like peptide-1) regulates insulin secretion, appetite, and gastric emptying — and is the basis for the blockbuster GLP-1 agonist drugs (semaglutide/Ozempic). Ghrelin, the "hunger hormone," is a peptide produced in the stomach. Cholecystokinin (CCK) signals satiety and stimulates bile and enzyme release.

7. Skin, Collagen, and Anti-Aging

Collagen-derived peptides — particularly those from hydrolyzed collagen — have been shown in clinical trials to stimulate fibroblast activity, increase skin elasticity, reduce wrinkle depth, and support joint cartilage integrity.^[7] Epithalon (Epitalon), a synthetic tetrapeptide based on the naturally occurring epithalamin from the pineal gland, has been studied for its telomere-lengthening and anti-aging effects by Russian researcher Dr. Vladimir Khavinson, who has published over 700 papers on peptide bioregulators.^[8]

What Are Peptides Needed For? The Consequences of Decline

Peptide production is not static — it declines significantly with age, chronic illness, nutritional deficiency, chronic stress, and environmental toxin exposure. The consequences of this decline are far-reaching:

• Growth hormone decline (driven by reduced GHRH and GHRP signaling) contributes to loss of muscle mass, increased visceral fat, reduced bone density, impaired sleep quality, and cognitive decline — the hallmarks of biological aging.
• Thymosin alpha-1 decline with age (thymic involution) is associated with reduced T-cell function, increased susceptibility to infection, reduced vaccine efficacy, and impaired cancer immunosurveillance.
• Collagen peptide decline manifests as joint pain, skin aging, gut permeability (leaky gut), and impaired wound healing.
• Neuropeptide dysregulation is implicated in depression, anxiety, chronic pain syndromes, and neurodegenerative disease.
• Antimicrobial peptide deficiency increases susceptibility to bacterial and viral infections and is associated with inflammatory bowel disease, psoriasis, and rosacea.
• GLP-1 insufficiency contributes to insulin resistance, type 2 diabetes, and obesity.

Dr. William Seeds, MD, a pioneer in peptide therapy and author of Peptide Protocols, has stated: "The decline of peptide signaling is not a side effect of aging — it IS aging, at the molecular level. Restoring peptide signaling is one of the most powerful levers we have for extending healthspan."^[9]

Peptides and Immune Disease: What the Research Shows

The relationship between peptides and immune disease is one of the most exciting and rapidly evolving areas of biomedical research. Several peptides have demonstrated significant immunomodulatory effects in the context of autoimmune disease, chronic infection, and immune deficiency.

Thymosin Alpha-1 (Tα1)

Thymosin alpha-1 is perhaps the most clinically validated immune-regulatory peptide. It is FDA-approved (as Zadaxin) in over 35 countries for the treatment of hepatitis B, hepatitis C, and as an adjunct to cancer chemotherapy. Research has demonstrated its ability to:

• Enhance T-helper cell (Th1) activity and restore Th1/Th2 balance in autoimmune conditions
• Increase NK cell cytotoxicity against tumor cells
• Reduce inflammatory cytokines (IL-6, TNF-alpha) in sepsis and COVID-19
• Improve vaccine response in immunocompromised patients

A landmark 2020 study published in Clinical Infectious Diseases found that thymosin alpha-1 significantly reduced mortality in severe COVID-19 patients by restoring T-cell function and reducing the cytokine storm.^[10]

Low Dose Naltrexone (LDN) and Endogenous Opioid Peptides

Low dose naltrexone works by transiently blocking opioid receptors, triggering a rebound upregulation of endogenous opioid peptides (endorphins and enkephalins). This rebound effect has potent anti-inflammatory and immunomodulatory consequences. Clinical evidence supports LDN's use in multiple sclerosis, Crohn's disease, fibromyalgia, and lupus.^[11] Dr. Bernard Bihari, who pioneered LDN research, documented remarkable remissions in autoimmune patients using this peptide-mediated mechanism.

VIP (Vasoactive Intestinal Peptide)

VIP is a 28-amino-acid neuropeptide with profound anti-inflammatory effects. It regulates Th17/Treg balance — a critical axis in autoimmune disease — and has been studied in rheumatoid arthritis, inflammatory bowel disease, and pulmonary hypertension. Research by Dr. Mario Delgado at the Spanish National Research Council has demonstrated VIP's ability to suppress autoimmune inflammation through multiple mechanisms.^[12]

LL-37 (Cathelicidin)

LL-37 is the primary human cathelicidin antimicrobial peptide. Beyond its direct antimicrobial activity, it modulates innate immune responses, promotes wound healing, and has demonstrated anti-tumor activity in several cancer cell lines. Deficiency of LL-37 is associated with increased susceptibility to skin infections, respiratory infections, and inflammatory skin conditions including rosacea and atopic dermatitis.^[13]

Peptides and Cancer: Emerging Research

The intersection of peptides and cancer biology is one of the most active areas of oncology research. Peptides are being investigated both as cancer-fighting agents and as delivery vehicles for targeted cancer therapy.

Immune Checkpoint and Peptide Vaccines

Peptide-based cancer vaccines work by presenting tumor-specific peptide antigens to the immune system, training T-cells to recognize and destroy cancer cells. Multiple clinical trials are underway for peptide vaccines targeting melanoma, lung cancer, colorectal cancer, and glioblastoma. The success of mRNA vaccines (which encode peptide antigens) in COVID-19 has dramatically accelerated interest in this approach for oncology.^[14]

Thymosin Alpha-1 in Oncology

Thymosin alpha-1 has been studied as an adjunct to chemotherapy and radiation, with evidence suggesting it can restore immune function suppressed by conventional cancer treatment, enhance the efficacy of checkpoint inhibitors, and reduce treatment-related infections. A meta-analysis published in Cancer Immunology, Immunotherapy found that Tα1 significantly improved overall survival in non-small cell lung cancer patients when combined with standard chemotherapy.^[15]

BPC-157 and Tumor Biology

BPC-157's role in cancer is nuanced and actively debated. Its pro-angiogenic (blood vessel-forming) properties — beneficial for wound healing — have raised theoretical concerns about potential tumor growth promotion, though no human studies have demonstrated this effect. Conversely, some animal research has shown anti-tumor activity in specific cancer models. This remains an area requiring further investigation, and BPC-157 is generally not recommended for patients with active malignancy until more data is available.^[16]

Anticancer Peptides (ACPs)

A growing class of molecules called anticancer peptides (ACPs) are being developed as targeted cancer therapies. These peptides selectively disrupt cancer cell membranes (which have different electrical charges than normal cells), inhibit tumor angiogenesis, induce apoptosis (programmed cell death), and can be engineered to deliver cytotoxic payloads directly to tumor cells — minimizing the systemic toxicity of conventional chemotherapy.^[17]

Dr. Dipak Panigrahy, cancer biologist at Harvard Medical School, has noted: "Peptide-based therapies represent one of the most promising frontiers in precision oncology — they offer the specificity of biologics with the manufacturing advantages of small molecules."^[18]

The Peptide Decline Timeline: When Does It Start?

Peptide production begins declining earlier than most people realize:

• Growth hormone peptides (GHRH, GHRP): Peak in adolescence; decline begins in the mid-20s, with a 14% reduction per decade thereafter.
• Thymosin alpha-1: The thymus gland begins involuting (shrinking) after puberty; by age 40, thymic output is dramatically reduced; by age 65, the thymus is largely replaced by fat tissue.
• Collagen peptides: Collagen synthesis peaks around age 25 and declines approximately 1% per year thereafter.
• Epithalon/pineal peptides: Pineal gland calcification begins in the 30s–40s, reducing melatonin and epithalamin production.
• GLP-1: GLP-1 secretion is impaired by insulin resistance, gut dysbiosis, and high-sugar diets — conditions that are increasingly prevalent from the 30s onward.

This progressive decline in peptide signaling is not inevitable — it is modifiable. Part 2 of this series covers exactly how to assess your peptide status and what you can do about it.

Continue Reading

• Peptides Part 2: How to Test for Deficiencies, Optimize Levels Naturally & When to Seek Expert Guidance

References

1. Huberman A. Huberman Lab Podcast, Episode 83: "Peptides — Master Regulators of Biology." Stanford University, 2022.
2. Craik DJ, Fairlie DP, Liras S, Price D. "The Future of Peptide-based Drugs." Chemical Biology & Drug Design, 2013;81(1):136–147.
3. Grand View Research. "Peptide Therapeutics Market Size Report." 2023.
4. Goldstein AL. "From lab to bedside: emerging clinical applications of thymosin alpha 1." Expert Opinion on Biological Therapy, 2009;9(5):593–608.
5. Goldstein AL. "Thymosin alpha1: a thymic hormone with broad clinical application." Annals of the New York Academy of Sciences, 2007;1112:1–7.
6. Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design, 2011;17(16):1612–1632.
7. Proksch E, et al. "Oral Supplementation of Specific Collagen Peptides Has Beneficial Effects on Human Skin Physiology." Skin Pharmacology and Physiology, 2014;27(1):47–55.
8. Khavinson VKh, et al. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bulletin of Experimental Biology and Medicine, 2003;135(6):590–592.
9. Seeds W. Peptide Protocols, Volume 1. Seeds Scientific Research & Performance Institute, 2018.
10. Liu Y, et al. "Thymosin alpha-1 reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells." Clinical Infectious Diseases, 2020;71(16):2150–2157.
11. Younger J, Parkitny L, McLain D. "The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain." Clinical Rheumatology, 2014;33(4):451–459.
12. Delgado M, et al. "Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease." Nature Medicine, 2001;7(5):563–568.
13. Vandamme D, et al. "A comprehensive summary of LL-37, the factotum human cathelicidin peptide." Cellular Immunology, 2012;280(1):22–35.
14. Melief CJ, et al. "Therapeutic cancer vaccines." Journal of Clinical Investigation, 2015;125(9):3401–3412.
15. Li Y, et al. "Thymosin alpha-1 as an adjuvant for cancer immunotherapy: a meta-analysis." Cancer Immunology, Immunotherapy, 2019;68(7):1117–1128.
16. Gwyer Findlay E, Currie SM, Davidson DJ. "Cationic host defence peptides: potential as antiviral agents." BioDrugs, 2013;27(5):479–493.
17. Marqus S, Pirogova E, Piva TJ. "Evaluation of the use of therapeutic peptides for cancer treatment." Journal of Biomedical Science, 2017;24(1):21.
18. Panigrahy D, et al. "Eicosanoids suppress tumor immunosurveillance and drive cancer progression." Cancer and Metastasis Reviews, 2021;40(2):629–642.